

■ **The WHO, Health Canada and the US FDA and the CDC* have all contacted ICN Pharmaceuticals regarding the availability of its IV formulation of ribavirin to treat the outbreak of SARS (severe acute respiratory syndrome).** Although clinical studies to support the use of IV ribavirin in the treatment of SARS have not been conducted, ICN is cooperating with the agencies and supplying ribavirin for investigational use only.

* US Centers for Disease Control and Prevention

ICN Pharmaceuticals Inc. ICN Pharmaceuticals Pledges to Supply Ribavirin for Investigational Use in Treating SARS. Media Release : 2 Apr 2003.

Available from: URL: <http://www.icnpharm.com>

809019802